IM Cannabis Corp.

IMCC

CA44969Q3070

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 08:23:53 28/05/2024 pm IST			5-day change	1st Jan Change
0.81 ^CAD	-6.90%		-8.99%	+76.09%

08/05	Transcript : IM Cannabis Corp., Q1 2024 Earnings Call, May 08, 2024
08/05	IM Cannabis Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

IM Cannabis Corp. Provides Revenue Guidance for the Second Quarter of 2021

July 23, 2021 at 06:46 pm IST

IM Cannabis Corp. provided revenue guidance for the second quarter of 2021. For the period, the company expects its net revenue in the second quarter of 2021 to be in the range of $11 million to $12 million, an approximate 30% sequential increase from the first quarter.

Latest news about IM Cannabis Corp.

Transcript : IM Cannabis Corp., Q1 2024 Earnings Call, May 08, 2024	08/05
IM Cannabis Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
IM Cannabis Corp. and Vessel Brand, Inc. Partner to Bring Vessel Cannabis Accessories to the Israeli Market	09/04	CI
IM Cannabis, Avant Brands Sign BLK MKT's Licensing Deal for German Medical Cannabis Market	04/04	MT
Transcript : IM Cannabis Corp., 2023 Earnings Call, Mar 28, 2024	28/03
IM Cannabis Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023	25/03	MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth	25/03	MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization	25/03	MT
IM Cannabis Corp. Announces German Government's Final Approval of Legalizing Cannabis	25/03	CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	28/02	MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	28/02	CI
Avant Brands Brief: Restructuring Loan Agreements to Extend Term and Decrease Payments	26/02	MT
IM Cannabis Brief: Says Received 180 Calendar Day Extension from Nasdaq Stock Market to Regain Compliance with Bid Price Rule	31/01	MT
IM Cannabis Rescheduling Final Payment of the Oranim Pharmacy Acquisition	12/01	MT
IM Cannabis Announced Conclusion of Planning and Construction Legal Proceedings Against Focus Medical	02/01	MT
IM Cannabis Notes New Israeli Cannabis Regulation Delayed by Three Months	08/12	MT
IM Cannabis Announces Receipt of Court Action	27/11	MT
Transcript : IM Cannabis Corp., Q3 2023 Earnings Call, Nov 13, 2023	13/11
IM Cannabis Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
IM Cannabis Secures $1.39 Million in Short-Term Debt	13/23/13	MT
IM Cannabis Corp. Announces Executive Changes	10/23/10	CI
IM Cannabis CFO Steps Down	19/23/19	MT
IM Cannabis Corp. Announces Departure of Itay Vago as CFO	19/23/19	CI
Transcript : IM Cannabis Corp., Q2 2023 Earnings Call, Aug 14, 2023	14/23/14

Chart IM Cannabis Corp.

Duration

Period

More charts

Company Profile

IM Cannabis Corp. is a Canada-based medical cannabis company. The Company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), which has a cultivation license to breed, grow and supply medical cannabis products in Israel. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel. The Company operates through Adjupharm GmbH in Europe, which is a medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses granted by German regulatory authorities that allow for import/export capability with requisite permits. The Company operates through Trichome and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.87 CAD

Average target price

3.45 CAD

Spread / Average Target

+296.55%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Recreational Pharmaceuticals

	1st Jan change	Capi.
IM CANNABIS CORP.	+76.09%	8.54M
CURALEAF HOLDINGS, INC.	+16.15%	3.42B
TRULIEVE CANNABIS CORP.	+104.38%	1.91B
GOODNESS GROWTH HOLDINGS, INC.	+182.54%	92.35M
ACREAGE HOLDINGS, INC.	+203.85%	50.34M

Recreational Pharmaceuticals

IM Cannabis Corp.

Equities

IMCC

CA44969Q3070

Pharmaceuticals

IM Cannabis Corp. Provides Revenue Guidance for the Second Quarter of 2021

Latest news about IM Cannabis Corp.

Chart IM Cannabis Corp.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sector Recreational Pharmaceuticals